OBJECTIVES AND DESIGN: A novel risk stratification algorithm estimating risk of death in patients with relapsed multiple myeloma starting second-line treatment was recently developed using multivariable Cox regression of data from a Czech registry. It uses 16 parameters routinely collected in medical practice to stratify patients into four distinct risk groups in terms of survival expectation. To provide insight into generalisability of the risk stratification algorithm, the study aimed to validate the risk stratification algorithm using real-world data from specifically designed retrospective chart audits from three European countries. PARTICIPANTS AND SETTING: Physicians collected data from 998 patients (France, 386; Germany, 344; UK, 268) and applied the risk stratification algorithm. METHODS: The performance of the Cox regression model for predicting risk of death was assessed by Nagelkerke's R2, goodness of fit and the C-index. The risk stratification algorithm's ability to discriminate overall survival across four risk groups was evaluated using Kaplan-Meier curves and HRs. RESULTS: Consistent with the Czech registry, the stratification performance of the risk stratification algorithm demonstrated clear differentiation in risk of death between the four groups. As risk groups increased, risk of death doubled. The C-index was 0.715 (95% CI 0.690 to 0.734). CONCLUSIONS: Validation of the novel risk stratification algorithm in an independent 'real-world' dataset demonstrated that it stratifies patients in four subgroups according to survival expectation.

Amgen Europe GmbH Rotkreuz Switzerland

Amgen Uxbridge UK

Department of Haematology University of Leuven Leuven Belgium

Department of Haematooncology University Hospital Ostrava Ostrava Czech Republic

Department of Internal Medicine University Hospital Heidelberg Heidelberg Germany

Institute of Health and Wellbeing University of Glasgow Glasgow Scotland UK

Pharmerit International Rotterdam The Netherlands

Zobrazit více v PubMed

Dimopoulos MA, Terpos E, Niesvizky R, et al. . Clinical characteristics of patients with relapsed multiple myeloma. Cancer Treat Rev 2015;41:827–35. 10.1016/j.ctrv.2015.07.005 PubMed DOI

Moreau P, de Wit E. Recent progress in relapsed multiple myeloma therapy: implications for treatment decisions. Br J Haematol 2017;179:198–218. 10.1111/bjh.14780 PubMed DOI

Yong K, Delforge M, Driessen C, et al. . Multiple myeloma: patient outcomes in real-world practice. Br J Haematol 2016;175:252–64. 10.1111/bjh.14213 PubMed DOI PMC

Moreau P. The future of therapy for relapsed/refractory multiple myeloma: emerging agents and novel treatment strategies. Semin Hematol 2012;49 Suppl 1:S33–46. 10.1053/j.seminhematol.2012.05.004 PubMed DOI

Raab MS, Cavo M, Delforge M, et al. . Multiple myeloma: practice patterns across Europe. Br J Haematol 2016;175:66–76. 10.1111/bjh.14193 PubMed DOI

Kim SM, Kim MJ, Jung HA, et al. . Comparison of the Freiburg and Charlson comorbidity indices in predicting overall survival in elderly patients with newly diagnosed multiple myeloma. Biomed Res Int 2014;2014:1–11. 10.1155/2014/437852 PubMed DOI PMC

Greipp PR, San Miguel J, Durie BGM, et al. . International staging system for multiple myeloma. J Clin Oncol 2005;23:3412–20. 10.1200/JCO.2005.04.242 PubMed DOI

Hari PN, Zhang M-J, Roy V, et al. . Is the International staging system superior to the Durie-Salmon staging system? A comparison in multiple myeloma patients undergoing autologous transplant. Leukemia 2009;23:1528–34. 10.1038/leu.2009.61 PubMed DOI PMC

Palumbo A, Avet-Loiseau H, Oliva S, et al. . Revised international staging system applied to real world multiple myeloma patients. J Clin Oncol 2015;33:2863–9. PubMed PMC

Jimenez-Zepeda VH, Duggan P, Neri P, et al. . Revised international staging system applied to real world multiple myeloma patients. Clin Lymphoma Myeloma Leuk 2016;16:511–8. 10.1016/j.clml.2016.06.001 PubMed DOI

Bustoros M, Mouhieddine TH, Detappe A, et al. . Established and novel prognostic biomarkers in multiple myeloma. Am Soc Clin Oncol Educ Book 2017;37:548–60. 10.14694/EDBK_175175 PubMed DOI

Tandon N, Rajkumar SV, LaPlant B, et al. . Clinical utility of the revised international staging system in unselected patients with newly diagnosed and relapsed multiple myeloma. Blood Cancer J 2017;7:e528. 10.1038/bcj.2017.13 PubMed DOI PMC

Hájek R, Jarkovsky J, Bouwmeester W, et al. . The value of risk stratification tools in multiple myeloma (Mm) in the real-world: validation of the Revised- international staging system (R-ISS) at initiation of treatment and relevance of the ISS and the R-ISS for risk stratification in the relapsed setting using data from the Czech registry of monoclonal gammopathies (RMG). Blood 2016;128:2418 10.1182/blood.V128.22.2418.2418 DOI

Hájek R, Jiri J, Walter B, et al. . Predictors of overall survival (OS) in patients with multiple myeloma (Mm) initiating first- and second-line treatment in the Czech Republic. Blood 2016;128:3607 10.1182/blood.V128.22.3607.3607 DOI

Bouwmeester W, Briggs A, van Hout B, et al. . Methodology of a novel risk stratification algorithm for patients with multiple myeloma in the relapsed setting. Oncol Ther 2019;7:141–57. 10.1007/s40487-019-00100-5 PubMed DOI PMC

Hájek R, Delforge M, Raab MS, et al. . Development and validation of a novel risk stratification algorithm for relapsed multiple myeloma. Br J Haematol 2019;187:447–58. 10.1111/bjh.16105 PubMed DOI PMC

Gonzalez-McQuire S, Dimopoulos M-A, Weisel K, et al. . Development of an initial conceptual model of multiple myeloma to support clinical and health economics decision making. MDM Policy Pract 2019;4:238146831881425. 10.1177/2381468318814253 PubMed DOI PMC

Radocha J, Pour L, Spicka I, et al. . Registry of monoclonal gammopathies (RMG) in the Czech Republic. Blood 2015;126:4514 10.1182/blood.V126.23.4514.4514 DOI

van Buuren S, Boshuizen HC, Knook DL. Multiple imputation of missing blood pressure covariates in survival analysis. Stat Med 1999;18:681–9410.1002/(SICI)1097-0258(19990330)18:6<681::AID-SIM71>3.0.CO;2-R PubMed DOI

Taylor JMG, Ankerst DP, Andridge RR. Validation of biomarker-based risk prediction models. Clin Cancer Res 2008;14:5977–83. 10.1158/1078-0432.CCR-07-4534 PubMed DOI PMC

Vergouwe Y, Moons KGM, Steyerberg EW. External validity of risk models: use of benchmark values to disentangle a case-mix effect from incorrect coefficients. Am J Epidemiol 2010;172:971–80. 10.1093/aje/kwq223 PubMed DOI PMC

Terpos ED MA, Kastritis E, Roussou M. External validation of the multiple myeloma risk-stratification algorithm in a real-world Greek data set. Poster presented at the European hematology. Association 23rd annual meeting 14-17 June, 2018.